

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Acute Myeloid Leukemia

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase III ADMIRAL trial comparing gilteritinib to chemotherapy for patients with acute myeloid leukemia (AML) with a FLT3 mutation demonstrated a significant improvement in overall survival (OS) with gilteritinib in which subgroup?**
  - Patients with newly diagnosed AML only
  - Patients with relapsed or refractory AML only
  - Patients with either newly diagnosed or relapsed/refractory AML
- 2. The Phase III VIALE-A trial evaluating azacitidine in combination with either venetoclax or placebo for patients with treatment-naïve AML who are ineligible for standard induction therapy demonstrated which clinical outcome with respect to OS and complete remission (CR) rate in the subgroup of patients with IDH1 or IDH2 mutations on the azacitidine/venetoclax arm?**
  - No statistically significant improvement in OS or CR rate
  - A statistically significant improvement in both OS and CR rate
  - A statistically significant improvement in OS but not CR rate
  - A statistically significant improvement in CR rate but not OS
- 3. In a report published by Fathi and colleagues in *JAMA Oncology* 2018 of the results of a Phase I/II trial of enasidenib monotherapy for patients with advanced hematologic cancers harboring IDH2 mutations, which of the following conclusions was drawn for the cohort of patients with relapsed or refractory AML?**
  - The occurrence of differentiation syndrome (DS) is predictive of response to therapy
  - The occurrence of DS is predictive of no response to therapy
  - The occurrence of DS is not predictive of response or lack of response to therapy
- 4. Which of the following statements best describes the occurrence of DNMT3A mutations in patients with AML?**
  - DNMT3A mutations rarely occur in AML
  - DNMT3A mutations can occur with NPM1 mutations in AML
  - DNMT3A mutations and NPM1 mutations are mutually exclusive in AML
- 5. Which of the following drug types best describes gemtuzumab ozogamicin?**
  - Hypomethylating agent
  - Bcl-2 inhibitor
  - Antibody-drug conjugate targeting CD33